A look at Sarepta’s earnings
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA[1.ribonucleic acid]-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. Sarepta is expected to release its Q2 2018 earnings on July 18. The chart below shows Sarepta’s revenue and EPS since Q1 2017, and estimates for Q2 2018.
Q2 2018 revenue estimates
In Q2 2018, analysts expect Sarepta’s revenue to rise ~93.6% YoY (year-over-year) to $67.8 million from $35.0 million, driven by strong sales of Exondys 51 (eteplirsen) and US demand. Exondys 51, an RNA-targeted therapy, is Sarepta’s only commercialized product.
Analysts expect Sarepta’s gross profit margin to narrow YoY in Q2 2018, to ~82.8% from ~98.5%. Also, due to higher R&D (research and development) and selling, general, and administrative expenses, Sarepta’s EBITDA margin is expected to be negative during Q2 2018. The company is expected to report a net adjusted loss of ~$50.3 million, with EPS of -$0.77.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!